SAB Biotherapeutics reported net income of -$23.20M for the quarter ended Jun 2026. This income statement covers 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.48M | 2.73M | 4.30M | 4.30M | 4.30M | 5.04M | 5.09M | 5.23M | 5.23M | 5.52M | 9.23M | 9.23M | 9.23M | 9.29M | 9.29M | 9.29M | 10.66M | 19.31M | 53.56M | 83.49M | |||
| Revenue & cost | |||||||||||||||||||||||
| Revenue | 14.68M | 11.06M | 11.80M | 6.35M | 3.59M | 2.16M | 0.58M | 0.09M | 1.27M | 0.31M | 0.94M | 0.26M | 0.11M | ||||||||||
| Operating items | |||||||||||||||||||||||
| Research & DevelopmentR&D | 15.07M | 10.65M | 13.32M | 8.58M | 7.35M | 7.14M | 4.54M | 3.66M | 4.02M | 4.30M | 8.15M | 6.82M | 7.83M | 7.65M | 7.66M | 7.00M | 8.97M | 10.73M | 13.40M | 16.17M | |||
| Selling, General & AdministrativeSG&A | 3.60M | 7.75M | 5.19M | 4.31M | 4.04M | 2.88M | 3.45M | 2.90M | 2.57M | 14.88M | 4.19M | 3.64M | 3.48M | 2.47M | 3.11M | 2.73M | 3.71M | 5.04M | 6.60M | 7.21M | |||
| Other Operating ExpensesOther Opex | |||||||||||||||||||||||
| Operating ExpensesOpex | 18.67M | 18.40M | 18.51M | 12.89M | 11.40M | 10.02M | 7.98M | 6.56M | 6.59M | 19.18M | 12.34M | 10.46M | 11.31M | 10.12M | 10.77M | 9.73M | 12.68M | 15.77M | 20.00M | 23.38M | |||
| Operating IncomeOp. Inc | -3.99M | -7.34M | -6.71M | -6.54M | -7.81M | -7.86M | -7.40M | -6.48M | -5.32M | -18.87M | -11.39M | -10.20M | -11.31M | -10.01M | -10.77M | -9.73M | -12.68M | -15.77M | -20.00M | -23.38M | |||
| EBIT | -3.99M | -7.34M | -6.71M | -6.54M | -7.81M | -7.86M | -7.40M | -6.48M | -5.32M | -18.87M | -11.39M | -10.20M | -11.31M | -10.01M | -10.77M | -9.73M | -12.68M | -15.77M | -20.00M | -23.38M | |||
| Non-operating items | |||||||||||||||||||||||
| Non Operating Interest Expenses | 0.08M | 0.07M | 0.07M | 0.07M | 0.07M | 0.09M | 0.09M | 0.08M | 0.07M | 0.08M | 0.08M | 0.09M | 0.08M | 0.07M | 0.07M | 0.06M | 0.04M | 0.06M | 0.06M | 0.06M | |||
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 0.01M | 0.01M | 0.02M | 0.02M | 0.03M | 0.06M | 0.03M | 0.01M | 0.48M | 0.50M | 0.37M | 0.28M | 0.14M | 0.06M | 0.01M | 0.66M | 0.70M | 1.05M | 1.71M | |||
| Other Non Operating IncomeOther Non Op Inc. | 0.00M | 7.79M | 1.67M | 0.00M | 0.82M | 0.10M | 0.34M | 0.48M | 0.37M | 0.75M | 0.85M | 0.55M | 0.29M | 0.77M | 1.53M | 0.63M | 0.35M | ||||||
| Non Operating IncomeNon Op. Inc. | -0.07M | -4.21M | 7.79M | 1.67M | 0.73M | 0.01M | 0.05M | -0.40M | 0.22M | -3.98M | 6.36M | 2.87M | 0.96M | -1.39M | 5.58M | -0.38M | 58.12M | -1.09M | 1.13M | 0.89M | |||
| Net income details | |||||||||||||||||||||||
| EBT | -4.06M | -11.55M | 1.08M | -4.87M | -7.08M | -7.85M | -7.35M | -6.88M | -5.10M | -22.86M | -5.03M | -7.34M | -10.35M | -9.94M | -10.78M | -9.78M | -12.07M | -15.13M | -19.01M | -21.73M | |||
| Tax ProvisionsTaxes | 0.09M | -0.09M | |||||||||||||||||||||
| Profit After TaxPAT | -4.06M | -11.55M | 0.99M | -4.78M | -7.08M | -7.87M | -7.35M | -6.88M | -5.10M | -22.86M | -5.03M | -7.34M | -10.35M | -11.56M | -5.20M | -10.11M | 45.53M | -16.75M | -18.87M | -23.20M | |||
| Income from Non-Controlling InterestsInc. Minority | 0.08M | 0.07M | 0.07M | 0.07M | 0.07M | 0.09M | 0.07M | 0.07M | 0.07M | -0.66M | 0.07M | 0.07M | |||||||||||
| Income from Continuing OperationsIncome (Continuing) | -4.06M | -11.55M | 0.99M | -4.78M | -7.08M | -7.85M | -7.35M | -6.88M | -5.10M | -22.86M | -5.03M | -7.34M | -10.35M | -9.94M | -10.78M | -9.78M | -12.07M | -15.13M | -19.01M | -21.73M | |||
| Consolidated Net IncomeConsol Net Inc. | -4.06M | -11.55M | 0.99M | -4.78M | -7.08M | -7.85M | -7.35M | -6.88M | -5.10M | -22.86M | -5.03M | -7.34M | -10.35M | -9.94M | -10.78M | -9.78M | -12.07M | -15.13M | -19.01M | -21.73M | |||
| Income towards Parent CompanyParent Net Inc | -4.06M | -11.55M | 0.99M | -4.78M | -7.08M | -7.85M | -7.35M | -6.88M | -5.10M | -22.86M | -5.03M | -7.34M | -10.35M | -9.94M | -10.78M | -9.78M | -12.07M | -15.13M | -19.01M | -21.73M | |||
| Net Income towards Common StockholdersNet Income | -4.06M | -11.55M | 0.99M | -4.78M | -7.08M | -7.87M | -7.35M | -6.88M | -5.10M | -22.86M | -5.03M | -7.34M | -10.35M | -11.39M | -5.20M | -10.11M | -12.07M | -15.13M | -18.87M | -22.49M | |||
| Additional items | |||||||||||||||||||||||
| EPS (Basic) | -2.75 | -4.23 | 0.23 | -1.11 | -1.64 | -1.81 | -1.46 | -1.36 | -0.97 | -4.14 | -0.54 | -0.79 | -1.12 | -1.23 | -0.56 | -1.09 | -1.13 | -0.78 | -0.35 | -0.28 | |||
| EPS (Diluted) | -1.56 | -4.23 | 0.22 | -1.11 | -1.64 | -1.81 | -1.46 | -1.36 | -0.97 | -4.14 | -0.54 | -0.79 | -1.12 | -1.23 | -0.56 | -1.09 | -0.15 | -0.25 | -0.35 | -0.28 | |||
| Shares Outstanding | 1.48M | 2.73M | 4.31M | 4.30M | 4.30M | 4.35M | 5.04M | 5.04M | 5.24M | 5.52M | 9.24M | 9.26M | 9.26M | 9.26M | 9.29M | 9.29M | 10.66M | 19.31M | 53.56M | 79.75M | |||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 2.60M | 2.73M | 4.58M | 4.30M | 4.30M | 4.35M | 5.04M | 5.04M | 5.24M | 5.52M | 9.24M | 9.26M | 9.26M | 9.26M | 9.29M | 9.29M | 77.86M | 61.34M | 53.56M | 79.75M | |||
| EBITDA | -3.99M | -7.34M | -6.71M | -6.54M | -7.81M | -7.86M | -7.40M | -6.48M | -5.32M | -18.87M | -11.39M | -10.20M | -11.31M | -10.01M | -10.77M | -9.73M | -12.68M | -15.77M | -20.00M | -23.38M | |||
| Interest ExpensesInt Expense | 0.08M | 0.07M | 0.07M | 0.07M | 0.07M | 0.09M | 0.09M | 0.08M | 0.07M | 0.08M | 0.08M | 0.09M | 0.08M | 0.07M | 0.07M | 0.06M | 0.04M | 0.06M | 0.06M | 0.06M | |||
| Tax Rate | 8.56 | 1.90 |